{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:13:38Z","timestamp":1792113218414,"version":"4.4.0"},"reference-count":83,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The interleukins IL-4 and IL-13 are increasingly recognized contributors to the pathogenesis of cutaneous T cell lymphomas (CTCLs), and their role in disease-associated pruritus is accepted. The prevailing Th2 profile in advanced CTCL underscores the significance of understanding IL-4\/IL-13 expression dynamics from the early stages of disease, as a shift from Th1 to Th2 may explain CTCL progression. Targeted agents blocking key cytokines of type 2 immunity are established therapeutics in atopic disorders and have a promising therapeutic potential in CTCL, given their involvement in cutaneous symptoms and their contribution to the pathogenesis of disease. IL-4, IL-13, and IL-31 are implicated in pruritus, offering therapeutic targets with dupilumab, tralokinumab, lebrikizumab, and nemolizumab. This review analyzes current knowledge on the IL-4\/IL-13 axis in mycosis fungoides and Sezary syndrome, the most common types of CTCL, examining existing literature on the pathogenetic implications with a focus on investigational treatments. Clinical trials and case reports are required to shed light on novel uses of medications in various diseases, and ongoing research into the role of IL-4\/IL-13 axis blockers in CTCL therapy might not only improve the management of disease-related pruritus but also provide in-depth insights on the pathophysiologic mechanisms of CTCL.<\/jats:p>","DOI":"10.3390\/life14020245","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T03:53:46Z","timestamp":1707450826000},"page":"245","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-2061","authenticated-orcid":false,"given":"Roberto","family":"Mazzetto","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Miceli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-7649","authenticated-orcid":false,"given":"Jacopo","family":"Tartaglia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9098-4124","authenticated-orcid":false,"given":"Christian","family":"Ciolfi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-0326","authenticated-orcid":false,"given":"Alvise","family":"Sernicola","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Alaibac","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood.2019004725","article-title":"Genome-Wide Transcriptome Analysis of the STAT6-Regulated Genes in Advanced-Stage Cutaneous T-Cell Lymphoma","volume":"136","author":"Gaydosik","year":"2020","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dobos, G., Pohrt, A., Ram-Wolff, C., Lebb\u00e9, C., Bouaziz, J.-D., Battistella, M., Bagot, M., and De Masson, A. (2020). Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers, 12.","DOI":"10.3390\/cancers12102921"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 Update of the WHO-EORTC Classification for Primary Cutaneous Lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205.e1","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary Cutaneous T-Cell Lymphoma (Mycosis Fungoides and S\u00e9zary Syndrome)","volume":"70","author":"Jawed","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1002\/ski2.300","article-title":"Unveiling the Hidden Struggles: Exploring the Profound Impact of Advanced Stage Cutaneous T-Cell Lymphoma on Quality of Life","volume":"3","author":"Ottevanger","year":"2023","journal-title":"Ski. Health Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"S\u00e9zary Syndrome and Mycosis Fungoides Arise from Distinct T-Cell Subsets: A Biologic Rationale for Their Distinct Clinical Behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.0906-6705.2004.00176.x","article-title":"Multilineage Progression of Genetically Unstable Tumor Subclones in Cutaneous T-cell Lymphoma","volume":"13","author":"Kempf","year":"2004","journal-title":"Exp. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Saulite, I., Hoetzenecker, W., Weidinger, S., Cozzio, A., Guenova, E., and Wehkamp, U. (2016). S\u00e9zary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/9717530"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant Inflammation in Cutaneous T-cell Lymphoma\u2014A Hostile Takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11899-015-0293-y","article-title":"Cutaneous T cell Lymphoma: An Update on Pathogenesis and Systemic Therapy","volume":"10","author":"Chung","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e124233","DOI":"10.1172\/jci.insight.124233","article-title":"Benign T Cells Drive Clinical Skin Inflammation in Cutaneous T Cell Lymphoma","volume":"4","author":"Crouch","year":"2019","journal-title":"JCI Insight"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CCO.0000000000000243","article-title":"Tumor Microenvironment in Mycosis Fungoides and S\u00e9zary Syndrome","volume":"28","author":"Gonzalez","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1159\/000531979","article-title":"Causes of Death in Cutaneous T-Cell Lymphoma Patients","volume":"239","author":"Lebas","year":"2023","journal-title":"Dermatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5021\/ad.2021.33.6.487","article-title":"The Role of Tumor Microenvironment in Mycosis Fungoides and S\u00e9zary Syndrome","volume":"33","author":"Liu","year":"2021","journal-title":"Ann. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood-2007-05-075176","article-title":"Lymphoma Dissemination: The Other Face of Lymphocyte Homing","volume":"110","author":"Pals","year":"2007","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/bjd\/ljad072","article-title":"Malignancy Risk in Patients with Atopic Dermatitis: A Population-Based Cohort Study","volume":"189","author":"Wan","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/cea.12178","article-title":"Epidemiological Associations of Allergy, IgE and Cancer","volume":"43","author":"Josephs","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semcancer.2021.12.003","article-title":"Molecular Pathogenesis of Cutaneous T Cell Lymphoma: Role of Chemokines, Cytokines, and Dysregulated Signaling Pathways","volume":"86","author":"Patil","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_19","first-page":"147","article-title":"Advanced-stage Mycosis Fungoides: Role of the Signal Transducer and Activator of Transcription 3, Nuclear factor-\u03baB and Nuclear Factor of Activated T Cells Pathways","volume":"182","author":"Cereceda","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/bjd.12578","article-title":"Lessons Learned from Gene Expression Profiling of Cutaneous T-Cell Lymphoma","volume":"169","author":"Dulmage","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT Signaling Is Important for Cutaneous T-Cell Lymphoma (CTCL) Pathogenesis and Cancer Progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"153477","DOI":"10.1016\/j.prp.2021.153477","article-title":"STAT6: A Review of a Signaling Pathway Implicated in Various Diseases with a Special Emphasis in Its Usefulness in Pathology","volume":"223","author":"Karpathiou","year":"2021","journal-title":"Pathol.-Res. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1346-8138.12440","article-title":"Thymus and Activation-regulated Chemokine as a Clinical Biomarker in Atopic Dermatitis","volume":"41","author":"Kataoka","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/1346-8138.13083","article-title":"New Aspects of the Clinicopathological Features and Treatment of Mycosis Fungoides and S\u00e9zary Syndrome","volume":"42","author":"Furue","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric Antigen Receptor Modified T Cells That Target Chemokine Receptor CCR4 as a Therapeutic Modality for T-cell Malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2018.00198","article-title":"New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma","volume":"8","author":"Fujii","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-16-0992","article-title":"Thymic Stromal Chemokine TSLP Acts through Th2 Cytokine Production to Induce Cutaneous T-Cell Lymphoma","volume":"76","author":"Takahashi","year":"2016","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.V99.2.609","article-title":"HLA-G Protein up-Regulation in Primary Cutaneous Lymphomas Is Associated with Interleukin-10 Expression in Large Cell T-Cell Lymphomas and Indolent B-Cell Lymphomas","volume":"99","author":"Urosevic","year":"2002","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000327553","article-title":"Specific IgE toward Allergenic Molecules Is a New Prognostic Marker in Patients with S\u00e9zary Syndrome","volume":"157","author":"Scala","year":"2012","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1158\/1078-0432.CCR-14-0707","article-title":"Deficient Cutaneous Antibacterial Competence in Cutaneous T-Cell Lymphomas: Role of Th2-Mediated Biased Th17 Function","volume":"20","author":"Wolk","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1189\/jlb.3MR0117-033R","article-title":"The IL-31\/IL-31 Receptor Axis: General Features and Role in Tumor Microenvironment","volume":"102","author":"Ferretti","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2340\/00015555-1345","article-title":"Serum IL-31 Levels Are Increased in Patients with Cutaneous T-Cell Lymphoma","volume":"92","author":"Ohmatsu","year":"2012","journal-title":"Acta Derm. Venerol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/12034754211027858","article-title":"Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis","volume":"26","author":"Belmesk","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and Therapy of Cutaneous T Cell Lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2567.1997.00325.x","article-title":"Extracorporeal Photochemotherapy Restores Thl\/Th2 Imbalance in Patients with Early Stage Cutaneous T-Cell Lymphoma","volume":"92","author":"Renzo","year":"1997","journal-title":"Immunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"adv00271","DOI":"10.2340\/00015555-3576","article-title":"Dupilumab Treatment in Two Patients with Cutaneous T-Cell Lymphomas","volume":"100","author":"Lazaridou","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.jacig.2023.100128","article-title":"Dupilumab for Cancer-Associated Refractory Pruritus","volume":"2","author":"Talmon","year":"2023","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jdv.17001","article-title":"Rapid and Sustained Control of Itch and Reduction in Th2 Bias by Dupilumab in a Patient with S\u00e9zary Syndrome","volume":"35","author":"Steck","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/exd.14859","article-title":"Dupilumab-Associated Ocular Adverse Events Are Predicted by Low Tear Break-up Time and Correlate with High IL-33 Tear Concentrations in Patients with Atopic Dermatitis","volume":"32","author":"Chiricozzi","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5070\/D3264048364","article-title":"Development of S\u00e9zary Syndrome Following the Administration of Dupilumab","volume":"26","author":"Tran","year":"2020","journal-title":"Dermatol. Online J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jaad.2022.12.001","article-title":"Diagnosis of Mycosis Fungoides or S\u00e9zary Syndrome after Dupilumab Use: A Systematic Review","volume":"88","author":"Jfri","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of Cutaneous T-Cell Lymphoma after Dupilumab: Case Review of 7 Patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00403-023-02652-z","article-title":"Dupilumab-Associated Mycosis Fungoides: A Cross-Sectional Study","volume":"315","author":"Hamp","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12185-022-03330-y","article-title":"Discordant Lymphomas of Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma Following Dupilumab Treatment for Atopic Dermatitis","volume":"116","author":"Nakazaki","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"46073","DOI":"10.1074\/jbc.M209560200","article-title":"Kinetic Analysis of the Interleukin-13 Receptor Complex","volume":"277","author":"Andrews","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood.V97.1.250","article-title":"Interleukin 13 and Interleukin 13 Receptor Are Frequently Expressed by Hodgkin and Reed-Sternberg Cells of Hodgkin Lymphoma","volume":"97","author":"Skinnider","year":"2001","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.V87.3.1022.bloodjournal8731022","article-title":"Interleukin-13 Inhibits Interleukin-2-Induced Proliferation and Protects Chronic Lymphocytic Leukemia B Cells from in Vitro Apoptosis","volume":"87","author":"Chaouchi","year":"1996","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.1085458","article-title":"Interleukin-4 and Interleukin-13 Signaling Connections Maps","volume":"300","author":"Hanson","year":"2003","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00262-003-0445-0","article-title":"Role of IL-13 in Regulation of Anti-Tumor Immunity and Tumor Growth","volume":"53","author":"Terabe","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/ijc.24067","article-title":"IL-13 Cytotoxin Has Potent Antitumor Activity and Synergizes with Paclitaxel in a Mouse Model of Oral Squamous Cell Carcinoma","volume":"124","author":"Kioi","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00063198-200301000-00004","article-title":"Interleukin-13 in Asthma","volume":"9","author":"Chiaramonte","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 Is Overexpressed in Cutaneous T-Cell Lymphoma Cells and Regulates Their Proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2217\/imt-2019-0190","article-title":"Small-Molecule-Based Immunotherapy for Immunologically Mediated Skin Conditions","volume":"12","author":"Sernicola","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-Cell Lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","article-title":"IL-13 Effector Functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100214","DOI":"10.1016\/j.xjidi.2023.100214","article-title":"Tralokinumab Effectively Disrupts the IL-13\/IL-13R\u03b11\/IL-4R\u03b1 Signaling Complex but Not the IL-13\/IL-13R\u03b12 Complex","volume":"3","author":"Tollenaere","year":"2023","journal-title":"JID Innov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"638325","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a Clinical Target for Pruritus Treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Miake, S., Tsuji, G., Takemura, M., Hashimoto-Hachiya, A., Vu, Y.H., Furue, M., and Nakahara, T. (2019). IL-4 Augments IL-31\/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20164053"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamadermatol.2023.2608","article-title":"Can Serum Biomarkers for Prurigo Nodularis Expose Pathophysiology or Just Treatment Response?","volume":"159","author":"Kashem","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: The \u201cItchy\u201d Cytokine in Inflammation and Therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): A Nuclear Cytokine from the IL-1 Family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-030-55617-4_8","article-title":"Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment","volume":"1290","author":"Rook","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5114\/ada.2020.96260","article-title":"The Ambiguous Pruritogenic Role of Interleukin-31 in Cutaneous T-Cell Lymphomas in Comparison to Atopic Dermatitis: A Review","volume":"37","author":"Olszewska","year":"2020","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved Pruritus Correlates with Lower Levels of IL-31 in CTCL Patients under Different Therapeutic Modalities","volume":"158","author":"Singer","year":"2015","journal-title":"Clin. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-Cell Lymphoma and Pruritus: The Expression of IL-31 and Its Receptors in the Skin","volume":"96","author":"Nattkemper","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/jdv.15075","article-title":"Inflammatory Cytokines and Peripheral Mediators in the Pathophysiology of Pruritus in Cutaneous T-Cell Lymphoma","volume":"32","author":"Lewis","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1600-0625.2010.01147.x","article-title":"Interferon-\u03b3 Induces Upregulation and Activation of the Interleukin-31 Receptor in Human Dermal Microvascular Endothelial Cells","volume":"19","author":"Feld","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and Safety of Vixarelimab, a Human Monoclonal Oncostatin M Receptor \u03b2 Antibody, in Moderate-to-Severe Prurigo Nodularis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2332\/allergolint.10-OA-0297","article-title":"Periostin Contributes to the Pathogenesis of Atopic Dermatitis by Inducing TSLP Production from Keratinocytes","volume":"61","author":"Shiraishi","year":"2012","journal-title":"Allergol. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00262-011-1059-6","article-title":"Increased Prevalence of Regulatory T Cells in the Lung Cancer Microenvironment: A Role of Thymic Stromal Lymphopoietin","volume":"60","author":"Li","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccr.2012.08.017","article-title":"Elevated Epidermal Thymic Stromal Lymphopoietin Levels Establish an Antitumor Environment in the Skin","volume":"22","author":"Demehri","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.4049\/jimmunol.178.11.6720","article-title":"Cutting Edge: Direct Action of Thymic Stromal Lymphopoietin on Activated Human CD4+ T Cells","volume":"178","author":"Rochman","year":"2007","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3109\/10428194.2014.919634","article-title":"CCR4+T Cell Recruitment to the Skin in Mycosis Fungoides: Potential Contributions by Thymic Stromal Lymphopoietin and Interleukin-16","volume":"56","author":"Tuzova","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2230.2008.02990.x","article-title":"Increased Serum Thymic Stromal Lymphopoietin Levels in Patients with Cutaneous T Cell Lymphoma","volume":"34","author":"Miyagaki","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody, in the Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Phase 2a Clinical Trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7697699","DOI":"10.1155\/2023\/7697699","article-title":"The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target","volume":"2023","author":"Luo","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Furue, M., and Furue, M. (2021). Interleukin-31 and Pruritic Skin. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091906"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kawana, Y., Suga, H., Kamijo, H., Miyagaki, T., Sugaya, M., and Sato, S. (2021). Roles of OX40 and OX40 Ligand in Mycosis Fungoides and S\u00e9zary Syndrome. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212576"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Sernicola, A., Ciolfi, C., Miceli, P., and Alaibac, M. (2023). Cutaneous Lymphoma and Antibody-Directed Therapies. Antibodies, 12.","DOI":"10.3390\/antib12010021"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/2\/245\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:57:48Z","timestamp":1760104668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/2\/245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":83,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["life14020245"],"URL":"https:\/\/doi.org\/10.3390\/life14020245","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}